An interventional study of Integration of a digital tool in Chronic Leukemia, sponsored by Versailles Hospital. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Versailles Hospital · Not applicable, Interventional, and Supportive care
The objective of this project is to evaluate, over a 12-month period, the feasibility of integrating a digital tool into the follow-up care of patients with chronic myeloid leukemia who have been off treatment for up to 2 years. Feasibility will be assessed based on the usage rate, defined as the proportion of patients who accessed the digital tool at least:
Versailles Hospital is the lead sponsor of 74 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Integration of a digital tool into the follow-up care of patients with CML who have been off treatment for up to 2 years.
Other: Integration of a digital tool
Integration of a digital tool into the follow-up care of patients with CML who have been off treatment for up to 2 years.
Feasibility will be assessed based on the usage rate, defined as the proportion of patients who accessed the digital tool at least: - once a month, if treatment interruption is ≤ 6 months; - once a quarter, if treatment interruption is > 6 months.
To evaluate, over a 12-month period, the feasibility of integrating a digital tool into the care of patients with chronic myeloid leukemia
Time frame: 12 months
Number of times patients used the device.
Assess how often the device is used.
Time frame: 12 months
The number of days between when the blood test is performed and when the IPA and the patient view the results on the device.
Assess the time it takes for the Study Nurse and the patient to access laboratory results.
Time frame: 12 months
The frequency with which patients contact the study nurse through the system's communication module.
Evaluate the use of the digital device's data exchange module between the patient and the Study Nurse
Time frame: 12 months
Anxiety scores will be assessed at enrollment, at M3, M6, and M12 using the 7-item Generalized Anxiety Disorder Screening Scale (GAD-7) (scores range from 0 to 21).
To study anxiety symptoms and their progression over the course of follow-up.
Time frame: 12 months
Changes in the GAD-7 anxiety score (0 to 21) based on the duration of treatment interruption (months) and the frequence
To examine the relationship between changes in anxiety scores based on the duration of treatment interruption and the use of the device.
Time frame: 12 months
Patient satisfaction will be assessed using a questionnaire designed specifically for this population, consisting of 9 items (with a score ranging from 0 to 36) and a numerical scale for overall satisfaction ranging from 0 to 10.
Assess patient satisfaction with the digital tool.
Time frame: 12 months
The tool's usability will be evaluated using the 10-item System Usability Scale (SUS) (0 to 100).
Evaluate the usability of the digital device.
Time frame: 12 months
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Versailles Hospital